Resistance of colon cancer cells to long‐term 5‐fluorouracil exposure is correlated to the relative level of Bcl‐2 and Bcl‐XL in addition to Bax and p53 status
Open Access
- 22 January 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 98 (4) , 498-504
- https://doi.org/10.1002/ijc.10146
Abstract
Defects in apoptosis have been implicated in chemoresistance of colon cancer cells. We report here the ability to resist to 5‐fluorouracil‐induced apoptosis of 8 colon cancer cell lines differing in p53 and bax status: p53−/0bax+/+ for TC7, SW480, HT‐29; p53+/+bax−/− for LS174T, LoVo; p53+/+ bax+/− for HCT116; p53+/+ or p53+/0bax+/+ for LS513 or HCT‐EB, respectively. To approximate to the in vivo therapy, the cell lines were exposed to a long‐term treatment of 5‐FU. The analysis of proteins implicated in the apoptotic pathway has shown that the independent analysis of p53 or bax status was not sufficient to predict the extent of drug‐resistance of all cell lines. In p53+/+ cell lines but not in p53−/0 cell lines, a low level of the pro‐apoptotic Bax protein was correlated with a greater resistance of cells to 5‐FU. In addition, we found that high levels of anti‐apoptotic Bcl‐2 and Bcl‐xL proteins combined with a low level of Bax were correlated to high 5‐FU resistance of wild‐type p53 cell lines. The same correlation was obtained for 2 out of 3 mutated p53 cell lines. In conclusion, the relative levels of Bcl‐2, Bcl‐xL and Bax may altogether contribute to determine the resistance of a majority of colon tumor cells to long‐term 5‐FU treatment, whatever their p53 status.Keywords
This publication has 27 references indexed in Scilit:
- Bcl‐XL Antisense Sensitizes Human Colon Cancer Cell Line to 5‐FluorouracilJapanese Journal of Cancer Research, 2000
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJournal of Clinical Investigation, 1999
- Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancersOncogene, 1998
- Bax Can Antagonize Bcl-XL during Etoposide and Cisplatin-induced Cell Death Independently of Its Heterodimerization with Bcl-XLJournal of Biological Chemistry, 1996
- A novel form of Epstein-Barr virus latency in normal B cells in vivoCell, 1995
- Tumor suppressor p53 is a direct transcriptional activator of the human bax geneCell, 1995
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- Drug resistance in oncology: from concepts to applicationsZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Adaptation to 5‐fluorouracil of the heterogeneous human colon tumor cell line ht‐29 results in the selection of cells committed to differentiationInternational Journal of Cancer, 1991
- A genetic model for colorectal tumorigenesisCell, 1990